[1] |
GRAHAM D. Muller and kirk's small animal dermatology[J]. New Zeal Vet J, 2014, 62(4):234.
|
[2] |
MUELLER R S, NUTTALL T, PROST C, et al. Treatment of the feline atopic syndrome-a systematic review[J]. Vet Dermatol, 2021, 32(1):43-60.
|
[3] |
LOPES N L, CAMPOS D R, MACHADO M A, et al. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats[J]. BMC Vet Res, 2019, 15(1):137.
|
[4] |
NOLI C, CENA T. Comparison of FEDESI and SCORFAD scoring systems for the evaluation of skin lesions in allergic cats[J]. Vet Dermatol, 2015, 26(6):481-e113.
|
[5] |
STEFFAN J, OLIVRY T, FORSTER S L, et al. Responsiveness and validity of the SCORFAD, an extent and severity scale for feline hypersensitivity dermatitis[J]. Vet Dermatol, 2012, 23(5):410-417.
|
[6] |
RYBNÍČEK J, LAU-GILLARD P J, HARVEY R, et al. Further validation of a pruritus severity scale for use in dogs[J]. Vet Dermatol, 2009, 20(2):115-122.
|
[7] |
HOBI S, LINEK M, MARIGNAC G, et al. Clinical characteristics and causes of pruritus in cats:a multicentre study on feline hypersensitivity-associated dermatoses[J]. Vet Dermatol, 2011, 22(5):406-413.
|
[8] |
HAZRA A, GOGTAY N. Biostatistics series module 3:comparing groups:numerical variables[J]. Indian J Dermatol, 2016, 61(3):251-260.
|
[9] |
VOGT A H, RODAN I, BROWN M, et al. AAFP-AAHA:feline life stage guidelines[J]. J Feline Med Surg, 2010, 12(1):43-54.
|
[10] |
YU H W, VOGELNEST L J. Feline superficial pyoderma:a retrospective study of 52 cases (2001-2011)[J]. Vet Dermatol, 2012, 23(5):448-455.
|
[11] |
OLIVRY T, STEFFAN J, FISCH R D, et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs[J]. J Am Vet Med Assoc, 2002, 221(3):370-377.
|
[12] |
DAY J M.Introduction:the immunological basis of allergic disease[M]//NOLI C, FOSTER A, ROSENKRANTZ W. Veterinary allergy. New York:John Wiley&Sons, 2014.
|
[13] |
PFEFFERLE P I, KEBER C U, COHEN R M, et al. The hygiene hypothesis-learning from but not living in the past[J]. Front Immunol, 2021, 12:635935.
|
[14] |
KOSHIBA R, OBA T, FUWA A, et al. Aggravation of food allergy by skin sensitization via systemic Th2 enhancement[J]. Int Arch Allergy Immunol, 2020, 182(4):292-300.
|
[15] |
SABIN B R, PETERS N, PETERS A T. Chapter 20:atopic dermatitis[J]. Allergy Asthma Proc, 2012, 33(Suppl 1):S67-S69.
|
[16] |
DONE S H, GOODY P C, EVANS S A, et al. Color atlas of veterinary anatomy:Volume 3.The dog and cat[M]. 2nd ed. Oxford:Elsevier, 2009:10.4.
|
[17] |
RZESZUTEK U. Successful treatment of a multi-drug-resistant severely pruritic hypersensitivity dermatitis in a cat[J]. Case Rep Vet Med, 2020, 2020:8897365.
|
[18] |
COSGROVE S B, WREN J A, CLEAVER D M, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis[J]. Vet Dermatol, 2013, 24(6):587-597.
|
[19] |
MOORE A, BURROWS A K, MALIK R, et al. Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat receiving oclacitinib for feline atopic skin syndrome[J]. Vet Dermatol, 2022, 33(5):435-439.
|
[20] |
GONZALES A J, BOWMAN J W, FICI G J, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy[J]. J Vet Pharmacol Ther, 2014, 37(4):317-324.
|
[21] |
CEVIKBAS F, LERNER E A. Physiology and pathophysiology of itch[J]. Physiol Rev, 2020, 100(3):945-982.
|
[22] |
FERRER L, CARRASCO I, CRISTÒFOL C, et al. A pharmacokinetic study of oclacitinib maleate in six cats[J]. Vet Dermatol, 2020, 31(2):134-137.
|